2021
Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors
Puthenpura V, Canavan ME, Poynter JN, Roth M, Pashankar FD, Jones BA, Marks AM. Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors. Pediatric Blood & Cancer 2021, 68: e28970. PMID: 33704901, PMCID: PMC8221084, DOI: 10.1002/pbc.28970.Peer-Reviewed Original ResearchConceptsHazard of deathCentral nervous system tumorsNervous system tumorsRace/ethnicitySocioeconomic statusSystem tumorsMultivariate Cox proportional hazards modelNon-Hispanic black patientsNon-Hispanic white patientsPrimary central nervous system tumorsCox proportional hazards modelEnd Results (SEER) databaseRetrospective cohort studyPrimary CNS tumorsYoung adult patientsNeuro-oncology patientsProportional hazards modelLowest SES tertileLow socioeconomic statusNHB patientsAYA patientsHazard ratioNHW patientsAdult patientsCohort study
2019
Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study.
Rodriguez-Galindo C, Krailo MD, Krasin MJ, Huang L, McCarville MB, Hicks J, Pashankar F, Pappo AS. Treatment of Childhood Nasopharyngeal Carcinoma With Induction Chemotherapy and Concurrent Chemoradiotherapy: Results of the Children's Oncology Group ARAR0331 Study. Journal Of Clinical Oncology 2019, 37: 3369-3376. PMID: 31553639, PMCID: PMC6920031, DOI: 10.1200/jco.19.01276.Peer-Reviewed Original ResearchConceptsEvent-free survivalChildhood nasopharyngeal carcinomaInduction chemotherapyConcurrent chemoradiotherapyStage IIBNasopharyngeal carcinomaCycles of ICCancer stage IIBPediatric-specific studiesCycles of cisplatinOverall survival estimatesAmerican Joint CommitteeDoses of cisplatinCumulative incidence estimatesRadiation dose reductionAdult regimensStable diseaseAdvanced diseasePartial responseMedian ageExcellent outcomesIncidence estimatesDose reductionPatientsJoint Committee
2017
Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study
Dicken BJ, Billmire DF, Krailo M, Xia C, Shaikh F, Cullen JW, Olson TA, Pashankar F, Malogolowkin MH, Amatruda JF, Rescorla FJ, Egler RA, Ross JH, Rodriguez‐Galindo C, Frazier AL. Gonadal dysgenesis is associated with worse outcomes in patients with ovarian nondysgerminomatous tumors: A report of the Children's Oncology Group AGCT 0132 study. Pediatric Blood & Cancer 2017, 65 PMID: 29286555, PMCID: PMC6219870, DOI: 10.1002/pbc.26913.Peer-Reviewed Original ResearchConceptsOvarian germ cell tumorsMalignant ovarian germ cell tumorsGerm cell tumorsEvent-free survivalNon-GD patientsOverall survivalGonadal dysgenesisMalignant germ cell tumorsAggressive chemotherapy regimenHigh-risk groupNondysgerminomatous tumorsChemotherapy regimenPure dysgerminomaPediatric patientsSac tumorBilateral gonadectomyCell tumorsWorse outcomesEmbryonal carcinomaPatientsStreak ovariesDysgenetic gonadsTumorsY chromosome materialGonadoblastoma